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Summary
To review the cumulative outcome of pre-implantation genetic diagnosis
(PGD) cycles performed for prevention of sickle cell disease (SCD). Cou-
ples referred for PGD for SCD between April 2012 and October 2017 were
included. Ovarian stimulation was performed using a short gonadotrophin-
releasing hormone (GnRH) antagonist protocol and follicle-stimulating
hormone injections. The GnRH agonist was used to trigger oocyte matura-
tion. Oocytes were fertilised using intracytoplasmic sperm injection.
Trophectoderm biopsy was performed on day 5 or 6 followed by vitrifica-
tion. Genetic testing was done using pre-implantation genetic haplotyping.
A total of 60 couples started 70 fresh PGD cycles (mean 12 cycles/couple)
and underwent a total of 74 frozen-embryo-transfer (FET) cycles (mean
13 FET/couple). The mean (SD) female age was 33 (44) years and the
mean (SD) anti-m€ullerian hormone level was 229 (28) pmol/l. The cumu-
lative live-birth rate was 54%/PGD cycle started and 63%/couple embarking
on PGD. The rate of multiple births was 8%. The cumulative outcome of
PGD treatment for prevention of SCD transmission is high and PGD treat-
ment should be offered to all at-risk couples.
Keywords: in vitro fertilisation (IVF), pre-implantation genetic diagnosis
(PGD), reproduction, sickle cell disease (SCD), single-gene disorder.
Introduction
Sickle cell disease (SCD) is an autosomal recessive haemoglo-
bin disorder that affects 300 000 newborns globally. In Eng-
land, the national newborn sickle cell screening programme
revealed sickle cell disorders in England are as common as
cystic fibrosis.1
SCD is characterised by lifelong morbidity and a shorter
life span.2 Prenatal diagnosis in the form of chorionic villus
sampling or amniocentesis offers couples who are at risk of
having a baby affected with the condition to opt for a termi-
nation of pregnancy. These invasive tests are associated with
a 1% risk of miscarriage.3 Non-invasive prenatal testing,
which has no procedure-related risk of miscarriage, is cur-
rently unavailable on the National Health Service (NHS)
because of the high false positive rate of almost 8%.4 Prenatal
diagnosis may prove undesirable to couples who find the
option of pregnancy termination unacceptable for religious
or personal reasons. Thus, alternative options available to
avoid giving birth to an affected child include a change of
partner, use of donor gametes, adoption or opting to forgo
having children altogether. Furthermore, several countries
have introduced premarital screening for at-risk couples.5–7
For these couples, pre-implantation genetic diagnosis
(PGD) offers a tangible choice. In the UK, couples who are
at risk of having a child affected with SCD and have no
unaffected children are entitled to a maximum of three
state-funded PGD cycles. There are a limited number of
centres licensed to provide PGD services in the UK of
which Guy’s and St Thomas’ NHS Foundation Trust
(GSTFT) is the largest. Almost half of the inner-city diverse
population that the GSTFT serves are from Black and
Minority Ethnic (BAME) groups, and hence the population
at risk of having a baby affected with SCD is significant. A
high rate of successful pregnancy would be important for
haematologists to know in order to refer patients for this
reproductive option, particularly if they already have a child
(or know of one) who has SCD. Furthermore, none of the
previous studies have assessed the cumulative success rate
of this reproductive option, which could undermine effec-
tive counselling offered to at-risk couples. This cohort study
provides an analysis of the cumulative outcome of PGD
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treatment in couples who have embarked on PGD for the
prevention of SCD during a 5-year period in an inner Lon-
don tertiary referral PGD centre.
Patients and methods
Patients
The PGD Centre at the GSTFT received tertiary referrals
from regional Fertility and Haematology centres looking after
couples who were identified as being at risk of conceiving a
child affected with SCD. Prior to attending the PGD Centre,
couples were sent a PGD information pack, including
detailed information of the NHS funding eligibility criteria,
PGD process and time scale, the likelihood of success, and
the associated risks of the procedure. Eligible couples were
seen by a senior PGD genetic counsellor and a reproductive
medicine specialist, where details of the PGD treatment were
explained as described previously.8
Design
A 5-year cohort study of couples undergoing PGD to prevent
SCD in the offspring.
In vitro fertilisation (IVF)/intracytoplasmic sperm
injection (ICSI) protocol
The gonadotrophin-releasing hormone (GnRH) antagonist
ovarian stimulation protocol was used in all cycles and the
choice of the daily dose of the follicle-stimulating hormone
(FSH) injections and monitoring of ovarian response was
carried out as described previously.9 Oocyte maturation was
induced using 50 iu of buserelin acetate (Suprecur, Sanofi,
Guildford, Surrey, UK). Transvaginal ultrasound-guided
retrieval of cumulus oocyte complexes was performed 36 h
after the buserelin injection and ICSI was used for oocyte
fertilisation as described elsewhere.8,10,11
PGD protocol
Embryos were assessed using an embryoscope. Opening of
the zona pellucida was accomplished on day 3 after fertilisa-
tion by laser penetration followed by extended IVF culture to
the blastocyst stage. On day 5 or 6 after fertilisation, fresh
blastocysts were assigned grades according to strict morpho-
logical criteria,12,13 which were not changed during the study
period. Criteria for blastocyst suitability for biopsy have been
described elsewhere.14 Biopsied blastocysts were vitrified
using a Cryolock device (Biotech Inc., Alpharetta, GA, USA)
and Vitrolife vitrification medium (FUJIFILM Irvine Scien-
tific, Newtownmountkennedy, Co. Wicklow, Ireland) on the
same day of biopsy. Genetic testing was carried out as
described previously.15
Frozen-thawed embryo transfer
One or two genetically suitable [non-carrier (HbAA) and
carrier (HbAS)] embryos were selected for transfer on day 6
of progesterone supplementation in a subsequent medicated
frozen embryo transfer cycle.14
Cycle outcome
The primary outcome was the live-birth rate. Secondary out-
comes were pregnancy, clinical pregnancy, implantation and
miscarriage rates. Pregnancy was defined as a positive human
chorionic gonadotrophin (hCG) test using a commercial uri-
nary testing kit 11 days after embryo transfer. A clinical
pregnancy was defined as the observation of fetal cardiac
activity on ultrasound scan at ≥4 weeks after embryo trans-
fer. Implantation was defined as the presence of an intra-
uterine gestational sac on ultrasound scan at ≥4 weeks after
embryo transfer. Miscarriage was defined as pregnancy loss
before 23 weeks gestation. All pregnancies were followed-up
until delivery. Live birth was defined as a live born infant
after 23 completed weeks of gestation.
Data collection and statistical analysis
For the purpose of this study, data were collected prospec-
tively. Patient demographic and baseline data, PGD cycle
characteristics and treatment outcomes were recorded in a
relational database. For normally distributed continuous vari-
ables, data were summarised as means with standard devia-
tions (SDs). For continuous variables, data were reported as
medians and interquartile ranges (IQRs). Categorical baseline
and dichotomous data were reported as absolute numbers
and percentages. Univariate analysis of the study outcome
measures and the associated clinical variables was performed
using two-sample t-test or Mann–Whitney test as appropri-
ate. StatView software (Statview Corp., Berkeley, CA, USA)
was used for statistical analysis. A P < 005 was considered
as statistically significant.
Ethical approval
This study was approved by the Local Research Ethics com-
mittee (Ref: 15407-1). Our study involved neither therapeutic
intervention nor change of our routine IVF protocols or data
collection. Each couple gave written informed consent for the
use of their data anonymously for audit and research pur-
poses upon enrolment into our IVF programme and before
starting an IVF cycle in accordance with the UK Human Fer-
tilisation and Embryology Authority (HFEA) regulations.
Results
A total of 60 couples were referred for PGD for the preven-
tion of SCD between April 2012 and Oct 2017, and
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undertook a total of 70 fresh PGD stimulation cycles. The
mean (SD) interval between the initial consultation to the
start of PGD treatment cycle was 5 (2) months. All cycles
were funded by the UK NHS.
Table I depicts patients’ demographics. In 52 couples,
both partners were sickle cell carriers with a genotype of
HbAS/HbAS and in eight couples one partner was affected
by the condition (HbSS) and the other partner was a carrier
(HbAS). Of these eight couples, the female partner was
affected in three cases (HbSS/HbAS) and the male partner
was affected in five (HbAS/HbSS). In 92% of couples
(n = 55), both partners were of Afro-Caribbean origin and
in 8% (n = 2) one partner was of Middle-Eastern/North
African ethnicity. Almost two-thirds of couples (n = 39)
lived in the lowest three most deprived quintiles as measured
by the English Index of Multiple Deprivation.16
Of the 60 female partners included in the study, 36 (60%)
had not previously had an affected pregnancy, 11 (19%) had
terminated a pregnancy affected with SCD after prenatal
diagnostic testing, and 13 (21%) had given birth to either
one (12) or two (one) children affected with SCD.
PGD cycle characteristics
All the women underwent the short GnRH antagonist ovar-
ian stimulation protocol and all 70 fresh PGD stimulation
cycles reached oocyte retrieval. The mean (SD) number of
oocytes retrieved was 16 (10), normally fertilised oocytes was
9 (6), blastocysts suitable for biopsy was 6 (4), and geneti-
cally suitable blastocysts for transfer was 4 (3).
In eight (11%) of the 70 fresh PGD cycles started, there
were no blastocysts suitable for biopsy on day 5 or 6 after
oocyte fertilisation. In one of the remaining 62 cycles, none
of the biopsied blastocysts were deemed genetically suitable
for transfer. Overall, genetic testing showed that 59% of blas-
tocysts biopsied were unaffected by SCD and were therefore
genetically suitable for transfer. Couples who had at least one
genetically suitable embryo for transfer underwent a total of
76 frozen-embryo-transfer (FET) cycles Table II, of which 61
(80%) were single-embryo transfers (SET) and 15 (20%)
were double-embryo transfers (DET).
PGD cycle outcome
There were no cases of misdiagnosis in any of the PGD
cycles. Following the 76 FET cycles performed, a positive uri-
nary hCG test was detected in 43 cycles (57%) and 42 of
these went on to achieve a clinical pregnancy (55%), with an
implantation rate of 50% (45/91). Of these, four miscarried
before 12-weeks gestation (9% miscarriage rate) and 38 had
live births resulting in a live-birth rate of 54% per fresh PGD
cycle started and 63% per couple starting PGD treatment. Of
the 38 live births, there were 35 (92%) singleton births, two
twin births and one triplet birth after a double embryo trans-
fer whereby one sac resulted in monozygotic twins and a sin-
gleton in the second sac.
Amongst the SET cycles, the clinical pregnancy rate per
embryo transfer was 59%. Of the 15 DET cycles, the clinical
pregnancy rate per embryo transfer was 40%. No cases of
misdiagnosis were reported in this series.
The three cases in which the female partner was affected
by SCD (HbSS/HbAS) involved women aged 31, 33 and
35 years. One woman (aged 35) underwent three cycles and
the other two women went through one cycle each. All three
women successfully gave birth. The live-birth rate per fresh
PGD cycle started was 60% and per couple was 100%.
Discussion
The uptake of PGD and the number of genetic conditions
for which PGD treatment is approved have been rising in the
UK in recent years.17 Therefore, the need for an accurate
assessment of the cumulative chance of success per cycle for
couples embarking on PGD treatment is paramount to
enable effective patient counselling. As a primary prevention
measure, timely identification of carrier couples is key to the
Table I. Patients’ demographics and sickle cell status.
Variable Value
Maternal age, years, mean (SD) 33 (43)
Paternal age, years, mean (SD) 37 (54)
Maternal BMI, kg/m2, mean (SD) 25 (3)
AMH level, pmol/l, mean (SD) 229 (28)
Sickle cell carrier status, n (%)
Both 52 (87)
Mother affected, Father carrier 3 (5)
Father affected, Mother carrier 5 (8)
AMH, anti-m€ullerian hormone; BMI, body mass index.
Table II. Pre-implantation genetic diagnosis (PGD) treatment
outcome.
Variable Value
Number of couples treated 60
Number of fresh PGD cycles started 70
Mean number of PGD cycles/couple 12
Mean number of cycles that did not reach biopsy stage 8
Number of cycles not reaching embryo transfer 1
Total number of FET cycles 76
Mean number of FET cycles/couple 13
Single-embryo transfers, n (%) 61 (80)
Double-embryo transfers, n (%) 15 (20)
Positive pregnancy test, n (%/FET cycle) 43 (57)
Clinical pregnancy, n (%/FET cycle) 42 (55)
Miscarriages, n (%/pregnancy) 4 (9)
Live births, n (%/fresh PGD cycle started) 38 (54)
Live births, n (%/couple having PGD treatment) 38 (63)
FET, frozen-embryo-transfer. Values are provided as mean values or
percentages.
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success of PGD, offering at-risk couples a valuable reproduc-
tive option and gradually reducing disease burden over time.
The present prospective cohort study from an inner-city
tertiary PGD referral centre in London showed that for cou-
ples at risk of having an offspring affected with SCD, the
live-birth rate for PGD per couple embarking on PGD treat-
ment was 63% after a mean of 12 fresh PGD cycles started.
These figures are significantly higher than previous reports
over the last two decades, in which the live-birth rate follow-
ing PGD ranged between 13% and 53%.18–21 Furthermore,
recently published data from the European Society of Human
Reproduction and Embryology (ESHRE) PGD Consortium22
reported a clinical pregnancy rate of 31% per embryo trans-
fer, compared to 55% clinical pregnancy rate per embryo
transfer in our present study. The embryo-implantation rate
was also higher in our present study compared to the study
of De Rycke et al.22 (50% vs. 23%).
Given that currently eligible couples for NHS-funded
PGD treatment are allowed up to three completed PGD
cycles, the cumulative live-birth rate per couple could be
even higher should unsuccessful couples opt to utilise all
available funded cycles,23 suggesting that PGD could be a
highly successful and cost-effective reproductive option for
at-risk couples.
The majority of transfers in our present study were SET,
resulting in a low multiple-birth rate (8%), adding to the
safety and acceptability of PGD as a realistic reproductive
option for couples at risk of conceiving a child affected with
SCD. Our low multiple-birth rate is consistent with the
upper limit of 10% set by the UK HFEA to curb the multi-
ple-birth rate in the UK, and is considerably lower than that
reported recently by the ESHRE PGD Consortium.22
The favourable success rates achieved in the present study
are likely to be related to a number of factors; young age of
the couples included in the study (mean maternal age
33 years), the consistency of our experienced PGD team, use
of trophectoderm biopsy and embryo vitrification techniques
that are known to yield favourable post-thaw embryo sur-
vival and implantation rates. In addition, only high quality
blastocysts were selected for the trophectoderm biopsy and
vitrification, and most of the couples included in the study
had no history of conception delay.
Conversely, PGD does result in the exclusion of geneti-
cally unsuitable embryos, thus the pool of embryos avail-
able for transfer is much smaller than that in the general
IVF population. Furthermore, women with SCD carry
unique risk factors that may negatively influence their abil-
ity to conceive including oxidative stress and ovarian sick-
ling.24,25 Therefore, the commendable rates achieved in the
present study are of the utmost significance for the SCD
population.
The economic burden to the NHS across an affected
individual’s lifetime needs to be carefully considered. It has
been reported that the cost of an acute painful sickle epi-
sode is estimated to be between £400–600/day.26
Additionally, it is important to consider the sequelae of
anaemia, including the requirement for repeated blood
transfusions and management of organ failure. Currently,
the overall cost of a PGD cycle is approximately £8000, and
with further refinements, including in the technique of
genetic testing and utilisation of all frozen embryos, the
cost of PGD could be reduced. It is therefore reasonable to
suggest that for at-risk couples, PGD needs to be part of
the reproductive decision making and should be considered
earlier in the process to maximise their chance of success.
Point of contact clinicians such as general practitioners,
haematologists and obstetricians involved in the care of
patients who are carriers or affected with SCD should
remain informed about the option of PGD. If utilised well,
PGD can serve as an effective primary prevention measure
in reducing the global burden of disease.
Despite many couples being aware of their genetic risks
either due to family history, prior screening or having an
affected child, a large proportion are unaware of the exis-
tence of PGD as a reproductive choice. A recent survey
revealed that only 44% of couples were aware of PGD and
all parents within the survey who were educated on the
option reported they would consider PGD for subsequent
children.27
Although such a high success rate of PGD for SCD will
help improve the uptake of PGD, other factors associated
with the acceptance of PGD need to be considered, including
moral, political and religious values.18,28 In a large cross-sec-
tional study involving 1006 respondents, the overall support
for PGD was only 66% in favour of applying PGD for dis-
eases causing lifelong disability.29 In earlier studies of carrier
parents, PGD is seen primarily as an opportunity to avoid
termination of pregnancy, and was seen more favourably
than adoption, donor insemination and egg donation.30 In
the same study, 85% of carriers of recessive genetic disorders
acknowledged that having a genetic link to the child is an
important factor in choosing PGD. Therefore, carefully
designed public health campaigns are required to highlight
this important reproductive option and its high cumulative
success rate, particularly when patients are able to utilise all
the embryos created in the fresh cycle through multiple FET
attempts. This enhanced awareness may also play a part in
influencing a change in the governing laws of some countries
to allow at-risk couples to reproduce as they now have a
viable, safe, successful and cost-effective treatment option to
have an unaffected child.
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